[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355704-105":59,"doc-detail-355704-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","double-jeopardy-risks-of-opioidbenzodiazepine-co-prescription-in-older-adults-with-gastrointestinal-cancer","Double Jeopardy - Risks of Opioid–Benzodiazepine Co-prescription in Older Adults with Gastrointestinal Cancer","","Opioid analgesics and benzodiazepines are commonly used to manage pain, anxiety, and insomnia in older adults with gastrointestinal cancers, but the consequences of their concurrent use remain incompletely characterized. A national cohort study used SEER–Medicare (2014–2018) to compare no exposure, opioid-only, and opioid–benzodiazepine co-prescription for overdose, falls/fractures, hospitalization, and 12-month all-cause mortality using time-varying Cox models.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/double-jeopardy-risks-of-opioidbenzodiazepine-co-prescription-in-older-adults-with-gastrointestinal-cancer/355704/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/double-jeopardy-risks-of-opioidbenzodiazepine-co-prescription-in-older-adults-with-gastrointestinal-cancer/355704.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What population and data source were used to study opioid–benzodiazepine co-prescription risks?","Question",{"text":113,"@type":114},"The study followed older adults with gastrointestinal cancer using linked Surveillance, Epidemiology, and End Results (SEER)–Medicare data from 2014 to 2018.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were exposure groups defined in the analysis?",{"text":118,"@type":114},"Daily exposure was categorized as no opioid/benzodiazepine, opioid-only, or opioid–benzodiazepine co-prescription, and outcomes were assessed within 12 months.",{"name":120,"@type":111,"acceptedAnswer":121},"Which adverse outcomes were evaluated, and what did the results show?",{"text":122,"@type":114},"Falls/fractures, all-cause hospitalization, opioid overdose, and all-cause mortality were evaluated; both opioid-only and co-prescribed patients had higher hazards than no exposure, and co-prescription added incremental risk versus opioid-only for hospitalization and mortality.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355704,1790453519,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","[https://doi.org/10.1245/s10434-026-19233-9](https://doi.org/10.1245/s10434-026-19233-9)  \nAnnals of Surgical Oncology (2026) 33:5693–5702  \nORIGINAL ARTICLE GASTROINTESTINAL ONCOLOGY  \nDouble Jeopardy: Risks of Opioid–Benzodiazepine Co‑prescription in Older Adults with Gastrointestinal Cancer  \nAreesh Mevawalla, MD1 · Azza Sarfraz, MD1 · Jasmine King, BS1 · Qaidar Alizai, MD1 · Meher Angez, MD1 ·  \nOdysseas P. Chatzipanagiotou, MD1 · Mujtaba Khalil, MD2 · Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA1  \nReceived: 6 October 2025 / Accepted: 27 January 2026 / Published online: 19 February 2026 © The Author(s) 2026  \nAbstract  \nBackground Opioid analgesics and benzodiazepines are frequently prescribed to manage pain, anxiety, and insomnia in older adults with gastrointestinal (GI) cancers, yet outcomes of concurrent use are incompletely defined.  \nPatients and Methods Using linked Surveillance, Epidemiology, and End Results (SEER)–Medicare (2014–2018), daily exposure was classified as no opioid/benzodiazepine, opioid only, or opioid–benzodiazepine co-prescription and overdose; falls/fractures, all-cause hospitalization, and all-cause mortality within 12 months were assessed. Time-varying Cox models compared opioid-only and co-prescription versus no exposure, and for incremental risk, co-prescription versus opioid-only. Results Among 26,896 patients (median age 74 years; 53.1% female), 5086 (18.9%) received concurrent opioid–benzodiazepine prescriptions and 2288 (8.5%) received opioids alone. Within 12 months, among patients unexposed, opioid-only, and co-prescribed, unadjusted first-event rates per 100,000 person-days (95% CI) were: falls/fractures 27.8 (26.7–28.9), 55.0 (47.1–63.9), and 61.0 (50.8–72.5); all-cause hospitalizations 393.0 (388.0–398.0), 439.0 (410.0–470.0), and 441.0 (406.0–480.0); overdose 1.40 (1.20–1.70), 6.20 (3.80–9.50), and 8.80 (5.32–13.83); and mortality 11.5 (10.8–12.2), 20.6 (15.9–26.1), and 29.6 (22.8–37.9), respectively (global p \u003C 0.001). In adjusted models versus no exposure, both opioid-only and co-prescribed patients had higher hazards of adverse outcomes. Using opioid-only as reference, co-prescription was associated with incremental hazards of all-cause hospitalization (HR 1.12, 95% CI 1.03–1.23) and all-cause mortality (HR 1.35, 95% CI 1.06–1.73) .  \nConclusions Opioid exposure was associated with elevated risk, while the addition of benzodiazepines conferred incremental increases in hospitalization and mortality versus opioid-only use.  \nKeywords Gastrointestinal cancer · Opioids · Benzodiazepines · Co-prescription · Older adults · Overdose · Falls · Hospitalization · Mortality · SEER–Medicare  \n* Timothy M. Pawlik, MD, PhD, MPH, MTS, MBA [tim.pawlik@osumc.edu](tim.pawlik@osumc.edu)  \n1 Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH  \n2 Department of Surgery, University of Wisconsin-Madison, Madison, WI  \nGastrointestinal (GI) malignancies, including colorectal, pancreatic, biliary tract, and primary liver cancers, impose a substantial health burden worldwide, accounting for roughly one-quarter of new cancer cases and one-third of cancer-related deaths globally.1,2 In the USA, these tumors represent a significant share of cancer mortality; colorectal and pancreatic cancer alone each claim roughly 50,000 lives annually.3,4 Patients with advanced GI cancers often experience profound symptom burdens, notably severe pain, psychological distress (e.g., anxiety), and insomnia.5 Effective management of these symptoms frequently requires pharmacotherapy, with opioid analgesics remaining the cornerstone of cancer pain control and benzodiazepines widely prescribed for anxiety and sleep disturbances.6  \nOpioids and benzodiazepines are therefore commonly co‐utilized in oncology care, despite guidelines urging caution with concurrent use.7 Prior studies show that opioid–benzodiazepine co-prescribing is frequent; one U.S. analysis repor","cbCainqVE3GlHJIl","https://ap.wps.com/l/cbCainqVE3GlHJIl","pdf",782645,"English","# Abstract\n## Background\n## Patients and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What population and data source were used to study opioid–benzodiazepine co-prescription risks?\",\"answer\":\"The study followed older adults with gastrointestinal cancer using linked Surveillance, Epidemiology, and End Results (SEER)–Medicare data from 2014 to 2018.\"},{\"question\":\"How were exposure groups defined in the analysis?\",\"answer\":\"Daily exposure was categorized as no opioid/benzodiazepine, opioid-only, or opioid–benzodiazepine co-prescription, and outcomes were assessed within 12 months.\"},{\"question\":\"Which adverse outcomes were evaluated, and what did the results show?\",\"answer\":\"Falls/fractures, all-cause hospitalization, opioid overdose, and all-cause mortality were evaluated; both opioid-only and co-prescribed patients had higher hazards than no exposure, and co-prescription added incremental risk versus opioid-only for hospitalization and mortality.\"}]","Double Jeopardy - Risks of Opioid–Benzodiazepine Co-prescription in Older Adults with Gastrointestinal Cancer | PDF",1790120568,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9dd16532007617ca59faa2117afa8ce.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/776f508599950f397c5194cf223f0cbb.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb6029eee4203674c07e3d8d1bebdb8e.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8a385ea973d4d30076d6c6ac2885117.webp",980,1301]